Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. STTK
stocks logo

STTK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.136
-63.28%
--
--
-0.140
-48.15%
--
--
-0.140
-41.67%
Estimates Revision
The market is revising No Change the revenue expectations for Shattuck Labs, Inc. (STTK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 91.61%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+91.61%
In Past 3 Month
Wall Street analysts forecast STTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STTK is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast STTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STTK is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 2.970
sliders
Low
2.00
Averages
3.00
High
4.00
Current: 2.970
sliders
Low
2.00
Averages
3.00
High
4.00
Wedbush
NULL
to
Outperform
initiated
$4
2025-09-08
Reason
Wedbush
Price Target
$4
2025-09-08
initiated
NULL
to
Outperform
Reason
Wedbush initiated coverage of Shattuck Labs with an Outperform rating and $4 price target.
Leerink
Faisal Khurshid
Outperform
to
Outperform
downgrade
$4 -> $2
2025-08-14
Reason
Leerink
Faisal Khurshid
Price Target
$4 -> $2
2025-08-14
downgrade
Outperform
to
Outperform
Reason
Leerink analyst Faisal Khurshid lowered the firm's price target on Shattuck Labs to $2 from $4 and keeps an Outperform rating on the shares after the company reported Q2 earnings and provided a pipeline update including expected Phase 1 trial initiation for SL-325 this quarter. The firm expects this to be a pivotal moment for Shattuck's turnaround story as the company transitions to a clinical-stage company, and thinks this should support new interest in its first-in-class DR3 approach in inflammatory bowel disease. Leerink notes that its change in price target is driven by additional shares outstanding, with minimal change in its other key modeling assumptions.
HC Wainwright & Co.
Joseph Pantginis
Hold
Reiterates
n/a
2025-03-27
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
n/a
2025-03-27
Reiterates
Hold
Reason
Needham
Gil Blum
Hold
Reiterates
n/a
2025-03-27
Reason
Needham
Gil Blum
Price Target
n/a
2025-03-27
Reiterates
Hold
Reason
Leerink Partners
Faisal Khurshid
Buy
Initiates
$4
2025-03-17
Reason
Leerink Partners
Faisal Khurshid
Price Target
$4
2025-03-17
Initiates
Buy
Reason
Leerink analyst Faisal A. Khurshid initiated coverage of Shattuck Labs with an Outperform rating and $4 price target. The firm views Shattuck Labs' pivot into inflammatory bowel disease as an underappreciated opportunity, with lead program SL-325 representing a first-in-class approach with potential to improve upon related, clinically validated, TL1A targeting programs. The company expects key Phase 1 milestones for SL-325 over the next 1 year, and Leerink is optimistic that these can spur investor interest in the turnaround story.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Shattuck Labs Inc (STTK.O) is -5.54, compared to its 5-year average forward P/E of -5.20. For a more detailed relative valuation and DCF analysis to assess Shattuck Labs Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.20
Current PE
-5.54
Overvalued PE
1.69
Undervalued PE
-12.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.53
Undervalued EV/EBITDA
-9.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
428.85
Current PS
0.00
Overvalued PS
1467.66
Undervalued PS
-609.95
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 6464.33% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 6464.33% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

STTK News & Events

Events Timeline

(ET)
2025-12-01
06:22:00
H.C. Wainwright Upgrades Shattuck Labs to Buy with $6 Price Target
select
2025-11-06 (ET)
2025-11-06
17:34:16
Shattuck Labs announces Q3 EPS of 14 cents, falling short of consensus estimate of 15 cents.
select
2025-08-21 (ET)
2025-08-21
10:18:55
Shattuck Labs announces IND approval for SL-325 to treat IBD.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
12-02Benzinga
Analyst Upgrade Enhances Confidence in Shattuck's Next-Gen Inflammatory Bowel Disease Treatment

  • Upgrade and Price Forecast: HC Wainwright upgraded Shattuck Labs Inc. from Neutral to Buy, setting a price target of $6, driven by the potential of its lead product candidate, SL-325, for treating inflammatory bowel disease (IBD).

  • Clinical Trial Progress: The company has initiated dosing in the Phase 1 clinical trial for SL-325, with completion of the single-ascending dose (SAD) and multiple-ascending dose (MAD) portions expected by the second quarter of 2026.

  • Market Competition and Differentiation: While competitors like Merck and Roche are advancing with TL1A-targeting therapies, Shattuck aims to differentiate itself by targeting the DR3 receptor, which may offer more durable inflammatory control.

  • Stock Performance: Following the upgrade, Shattuck Labs' stock (STTK) rose by 13.3%, reaching $2.38.

[object Object]
Preview
1.0
11-20Newsfilter
Shattuck Labs to Attend Investor Conferences Scheduled for December

  • Company Overview: Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors for inflammatory and immune-mediated diseases, with a lead program, SL-325, currently in Phase 1 clinical trials.

  • Upcoming Conferences: The company's management, led by CEO Taylor Schreiber, will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and the Evercore ISI 8th Annual HealthCONx Conference on December 4, 2025, featuring presentations and one-on-one meetings.

  • SL-325 Details: SL-325 is a potential first-in-class DR3 blocking antibody designed for a complete blockade of the DR3/TL1A pathway, showing high affinity and superior activity in preclinical studies, with a favorable safety profile in non-human primates.

  • Investor Relations: For more information, interested parties can visit Shattuck Labs' website or contact Andrew R. Neill, the Chief Financial Officer, for investor inquiries.

[object Object]
Preview
1.0
10-02Newsfilter
Shattuck Labs to Take Part in Upcoming Wedbush Securities Key Opinion Leader and Company Panel

  • Company Announcement: Shattuck Labs, Inc. will participate in a panel discussion at the United European Gastroenterology Week (UEGW) Conference 2025, focusing on key takeaways from the event, with CEO Taylor Schreiber as a participant.

  • Product Development: Shattuck is advancing SL-325, a potential first-in-class antibody targeting the DR3/TL1A pathway for inflammatory bowel disease, currently in Phase 1 clinical trials, demonstrating promising preclinical results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Shattuck Labs Inc (STTK) stock price today?

The current price of STTK is 2.97 USD — it has increased 14.23 % in the last trading day.

arrow icon

What is Shattuck Labs Inc (STTK)'s business?

Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

arrow icon

What is the price predicton of STTK Stock?

Wall Street analysts forecast STTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STTK is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Shattuck Labs Inc (STTK)'s revenue for the last quarter?

Shattuck Labs Inc revenue for the last quarter amounts to 1,000K USD, decreased -66.63 % YoY.

arrow icon

What is Shattuck Labs Inc (STTK)'s earnings per share (EPS) for the last quarter?

Shattuck Labs Inc. EPS for the last quarter amounts to -0.14 USD, decreased -57.58 % YoY.

arrow icon

What changes have occurred in the market's expectations for Shattuck Labs Inc (STTK)'s fundamentals?

The market is revising No Change the revenue expectations for Shattuck Labs, Inc. (STTK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 91.61%.
arrow icon

How many employees does Shattuck Labs Inc (STTK). have?

Shattuck Labs Inc (STTK) has 44 emplpoyees as of December 05 2025.

arrow icon

What is Shattuck Labs Inc (STTK) market cap?

Today STTK has the market capitalization of 187.31M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free